[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100311847":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":36,"centralContacts":31,"locations":40,"responsibleParty":52,"collaborators":31,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":31,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":31,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":31,"overallStatus":74,"whyStopped":31,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Idorsia Pharmaceuticals Ltd.","INDUSTRY",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"Treatment A","ACTIVE_COMPARATOR","Rosuvastatin Day 1",[13],"Drug: Rosuvastatin",{"label":15,"type":16,"description":17,"interventionNames":18},"Treatment B1","EXPERIMENTAL","ACT-541468 Day 5 to Day 7",[19],"Drug: ACT-541468",{"label":21,"type":22,"description":23,"interventionNames":24},"Treatment B2","OTHER","Rosuvastatin Day 8; ACT-541468 Day 8 to Day 12",[13,19],[26,32],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","Rosuvastatin","10 mg tablet",[9,21],null,{"type":27,"name":33,"description":34,"armGroupLabels":35,"otherNames":31},"ACT-541468","25 mg hard capsule",[15,21],[37],{"name":38,"affiliation":5,"role":39},"Clemens Mühlan","STUDY_DIRECTOR",[41],{"facility":42,"status":31,"city":43,"state":31,"zip":44,"country":45,"countryCode":31,"cosmosGeoPoint":46,"geoPoint":51,"contacts":31},"Cepha s.r.o.","Pilsen","32300","Czechia",{"type":47,"coordinates":48},"Point",[49,50],13.37759,49.74747,{"lat":50,"lon":49},{"type":53,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100311847","phase-1-a-study-in-healthy-male-subjects-to-investigate-whether-administration-of-act-541468-can-affect-the-fate-in-the-body-amount-and-time-of-presence-in-the-blood-of-rosuvastatin-100311847",false,"NCT03339752","A Study in Healthy Male Subjects to Investigate Whether Administration of ACT-541468 Can Affect the Fate in the Body (Amount and Time of Presence in the Blood) of Rosuvastatin","A Single-center, Open-label, One-sequence, Two-treatment Study to Investigate the Effect of ACT-541468 at Steady State on the Pharmacokinetics of Rosuvastatin in Healthy Male Subjects","Inclusion Criteria:\n\n* Signed informed consent in the local language prior to any study mandated procedure;\n* Healthy male subjects aged 18 to 45 years (inclusive) at screening;\n* Body mass index of 18.0 to 28.0 kg\u002Fm2 (inclusive) at screening;\n* Healthy on the basis of physical examination, cardiovascular assessments and laboratory tests.\n\nExclusion Criteria:\n\n* Known allergic reactions or hypersensitivity to ACT-541468, rosuvastatin, any drug of the same classes, or any of their excipients;\n* Any contraindication for rosuvastatin treatment;\n* History or clinical evidence of myopathy;\n* Asian or Indian-Asian ethnicity;\n* Known hypersensitivity or allergy to natural rubber latex;\n* Previous exposure to ACT-541468;\n* Treatment with rosuvastatin within 3 months prior to screening;\n* Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.",true,"MALE","18 Years","64 Years",{"count":66,"type":67},20,"ACTUAL","INTERVENTIONAL",[70],"PHASE1","A study in healthy male subjects to investigate whether administration of ACT-541468 can affect the fate in the body (amount and time of presence in the blood) of rosuvastatin",[73],"Healthy Subjects","COMPLETED","2017-12-08",{"date":77,"type":67},"2017-12-11",{"date":79,"type":67},"2017-10-30",{"date":81,"type":67},"2017-12-02",{"name":5,"class":6},1]